Chinese financial management firm Jinsheng Capital has partnered with Shenzhen-listed biopharma enterprise Walvax Biotechnology to set up Zhuhai Hengqin Walvax, a private equity (PE) fund with a focus on biomedicine investments, according to a company statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
